TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35113137
Drug: Intravitreal pegcetacoplan
Normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravitreal pegcetacoplan every other month (15 mg)
Study: 33498220
Drug: High NO3‐,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High NO3‐, low NO2‐ (HL; 572 mg NO3‐, 32 mg NO2‐)
Study: 33498220
Drug: Medium NO3‐,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium NO3‐, medium NO2‐ (MM; 280 mg NO3‐, 237 mg NO2‐)
Study: 33498220
Drug: Low NO3‐,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low NO3‐, medium NO2‐ (LM; 43 mg NO3‐, 262 mg NO2‐)
Study: 33498220
Drug: Placebo (PL;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL; low NO3‐, low NO2‐: 8 mg NO3‐, 5.8 mg NO2‐)
Study: 32946355
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (NFT)
Study: 33734043
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no anti-inflammatory therapy)
Study: 34538546
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of 8-mg intravenous dexamethasone (1D-group)
Study: 34538546
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of 8-mg intravenous dexamethasone (2D-group)
Study: 34648568
Drug: Immersive Virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immersive Virtual Reality (IVR) intervention for three sessions: 4 hours before chemotherapy, 5 minutes before and during the first course chemotherapy, and 5 minutes before and during the second course chemotherapy.
Study: 32536538
Drug: Liposomal lidocaine-prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal lidocaine-prilocaine formulation
Study: 32536538
Drug: Non-liposomal lidocaine-prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-liposomal lidocaine-prilocaine formulation
Study: 35698000
Drug: Secukinumab low
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab low dose (LD) 75/75/150 mg
Study: 35698000
Drug: Secukinumab high
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab high dose (HD) 75/150/300 mg
Study: 35129211
Drug: Binocular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binocular treatment
Study: 33713826
Drug: Post-discharge low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-discharge low-molecular-weight heparin (LMWH) injections once-daily for 30 days
Study: 33713826
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections once-daily for 30 days
Study: 34787919
Drug: TMFI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMFI treatment (Tixel®, Novoxel®, Israel)
Study: 34787919
Drug: NAFL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAFL treatment (non‐ablative fractional 1565 nm laser, ResurFX®, Lumenis, Israel)
Study: 34787919
Drug: Both TMFI
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both TMFI and NAFL treatments
Study: 35413873
Drug: Silver diamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver diamine fluoride (SDF) treatment
Study: 35413873
Drug: Standard package
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard package of glass ionomer sealants and atraumatic restorative treatment (ART)
Study: 35413873
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of SDF and standard treatment
Study: 32398581
Drug: Control (sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (sham leg wrapping and saline infusion)
Study: 34553463
Drug: Ashwagandha root
Normalized name: ashwagandha root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ashwagandha root extract (300 mg twice daily)
Study: 32051393
Drug: CCR3 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCR3 inhibitor SB328437
Study: 35310186
Drug: Crizotinib combined
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Crizotinib combined with chemotherapy (EG)
Study: 35310186
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (CG)
Study: 33793050
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg vitamin C from drink
Study: 33793050
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg vitamin C from kiwifruit
Study: 32609534
Drug: Goreisan (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goreisan (2.5 g orally on the night before surgery and on the morning of surgery)
Study: 33145897
Drug: RCTs evaluating
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCTs evaluating outcomes relevant to children's oral health; specific interventions not available.
Study: 34801112
Drug: PfSPZ Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ Vaccine (1.8 x 10^6 PfSPZ)
Study: 34510395
Drug: Oral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplementation with sucrosomial magnesium associated with therapeutic exercise
Study: 33512679
Drug: Therapeutic cancer
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic cancer vaccines, specific details not available.
Study: 33512679
Drug: Combination partners
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination partners (e.g., checkpoint inhibitors), specific details not available.
Study: 33512679
Drug: Randomized, phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized, phase 3 studies of therapeutic cancer vaccines, specific details not available.
Study: 34652627
Drug: 10% (20AA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% (20AA) compound AA injection
Study: 34652627
Drug: 8.5% (18AA‐II)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.5% (18AA‐II) compound AA injection
Study: 34652627
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition support therapy with iso‐nitrogen and iso‐calorie
Study: 35341360
Drug: VR-based mirror
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR-based mirror therapy (VR-MT)
Study: 33745372
Drug: Conventional occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional occupational therapy (COT)
Study: 33050728
Drug: Automated insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated insulin delivery
Study: 34346295
Drug: Chitosan at
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan at 0 mg/kg concentrate
Study: 34346295
Drug: Chitosan at
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan at 400 mg/kg concentrate
Study: 34346295
Drug: Chitosan at
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan at 800 mg/kg concentrate
Study: 34346295
Drug: Chitosan at
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan at 1200 mg/kg concentrate
Study: 34346295
Drug: Chitosan at
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan at 1600 mg/kg concentrate
Study: 616852791
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: tube voltage 100 kV; contrast agent iohexol (350 mg I/ml), reconstructed by filtered back projection
Study: 616852791
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: tube voltage 80 kV; contrast agent iodixanol (270 mg I/ml), reconstructed by algebraic reconstruction technique
Study: 32243576
Drug: O-R brush
Normalized name: OSTOMY SET,STERILE O.R.GUARDIAN H#4673
Approvals — FDA: no, EMA: no, PMDA: no
Description: O-R brush (Oral-B iO)
Study: 35034345
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 25000 I.U. oral solution under fed conditions
Study: 33522946
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 500,000 IU cholecalciferol (5 capsules of 100,000 IU)
Study: 616836595
Drug: Anhydrous caffeine
Normalized name: Anhydrous caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anhydrous caffeine (5 mg/kg)
Study: 35799756
Drug: Hydroxychloroquine Sulfate
Normalized name: Hydroxychloroquine Sulfate
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine Sulfate (200 mg orally 8 hourlies thrice a day for 5 days)
Study: 35799756
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Hydroxychloroquine, Oseltamivir, and Azithromycin
Study: 32151803
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) at 10 mg/kg/day up-titrated to 20-30 mg/kg/day for 12 weeks
Study: 32151803
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 30 mg/kg/day
Study: 33756376
Drug: Integrated Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Exposure Therapy (I-PE)
Study: 33756376
Drug: Integrated Coping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Coping Skills Therapy (I-CS)
Study: 34896126
Drug: Topical Chlorhexidine
Normalized name: chlorhexidine Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Chlorhexidine 0.2%
Study: 34896126
Drug: Topical Natamycin
Normalized name: Natamycin
DrugBank: Natamycin (DB00826)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Natamycin 5%
Study: 32782077
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EMLA cream and massage
Study: 33706032
Drug: TB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TB treatment support tools (TB‐TSTs)
Study: 34222086
Drug: Methylethylpiridinol addition
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylethylpiridinol addition to therapy
Study: 33626929
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy and local therapy (radiation, surgery, thermal ablation)
Study: 35251416
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 ml infiltration injection)
Study: 35251416
Drug: Methylprednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (1 ml infiltration injection)
Study: 34281377
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (intravenous alteplase)
Study: 34907038
Drug: Sociological variety
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sociological variety indicators (e.g., crowding, movement, livelihoods, recreational activity)
Study: 34907038
Drug: Socially open
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Socially open communities with poor ventilation (e.g., watching video shows)
Study: 34907038
Drug: Adjustments to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustments to socio-spatial aspects (e.g., increasing ventilation on transport)
Study: 33338662
Drug: Nebulized sodium
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized sodium nitrite (15 mg twice daily)
Study: 34182998
Drug: BGF 320/14.4/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGF 320/14.4/10 μg
Study: 35512458
Drug: BGF 160/14.4/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGF 160/14.4/10 μg
Study: 34182998
Drug: GFF 14.4/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFF 14.4/10 μg
Study: 34182998
Drug: BFF 320/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BFF 320/10 μg
Study: 33270487
Drug: Men-AC vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men-AC vaccine
Study: 33270487
Drug: Lanzhou-AC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanzhou-AC vaccine (Control)
Study: 36004504
Drug: Intradermal BTX‐A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal BTX‐A injection (50‐65 U)
Study: 36004504
Drug: Intradermal normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal normal saline (NS) injection
Study: 36283748
Drug: Dim light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim light therapy
Study: 32245464
Drug: Palovarotene 20
Normalized name: palovarotene
DrugBank: Palovarotene (DB05467)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palovarotene 20 mg/day for 4 weeks, then 10 mg/day for 8 weeks after left hip fracture surgery.
Study: 32245464
Drug: Palovarotene 20
Normalized name: palovarotene
DrugBank: Palovarotene (DB05467)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palovarotene 20 mg/day started at fracture occurrence, continued for 4 weeks, then reduced to 10 mg/day for 8 weeks after right hip fracture surgery.
Study: 35898773
Drug: Compound Danshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Danshen injection combined with magnesium sulfate
Study: 33904664
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml of Mountain Dew® (caffeinated soft drink sweetened with high-fructose corn syrup)
Study: 33904664
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml of tap water (H2O)
Study: 36378553
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (1 g/day; 1.2:1 ratio of eicosapentaenoic to docosahexaenoic acid)
Study: 34951021
Drug: Best standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best standard treatment (BST)
Study: 34795952
Drug: Mirogabalin (clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirogabalin (clinical dose) added to conventional therapy (non-steroidal anti-inflammatory drugs and/or acetaminophen) for 8 weeks
Study: 34795952
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (non-steroidal anti-inflammatory drugs and/or acetaminophen) without mirogabalin
Study: 32725772
Drug: Cisplatin dose
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin dose per kilogram lean body mass (LBM) in the first course
Study: 32725772
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (concurrent platinum–etoposide chemotherapy and thoracic radiotherapy)
Study: 35804404
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (no treatment)
Study: 34906334
Drug: Ponatinib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib (30 mg daily) with FLAG-IDA (fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor)
Study: 34906334
Drug: Ponatinib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib (30 mg daily) with FLAG-IDA
Study: 33091752
Drug: L-carnitine (LC)
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-carnitine (LC) supplementation at 150 mg/kg/d for 12 weeks
Study: 35569569
Drug: Oral motor
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral motor intervention combined with non-nutritive sucking
Study: 33356011
Drug: Prazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (1 mg/day for 1 week)
Study: 34856379
Drug: Standard-of-care treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care treatment (n = 36)
Study: 33384915
Drug: Preventure intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preventure intervention delivered by school staff (two 90-minute group sessions incorporating cognitive-behavioural therapy and motivational interviewing)
Study: 38581534
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors (AIs)
Study: 34119421
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g flaxseed supplementation
Study: 34119421
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g flaxseed supplementation
Study: 34906295
Drug: EndoMT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: EndoMT group (no treatment)
Study: 34906295
Drug: Blank group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blank group (no treatment)
Study: 34565678
Drug: Bedinvetmab (0.5–1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedinvetmab (0.5–1.0 mg kg–1, n = 141)
Study: 34565678
Drug: Bedinvetmab (0.5–1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedinvetmab (0.5–1.0 mg kg–1)
Study: 32455620
Drug: DieTBra +
Approvals — FDA: no, EMA: no, PMDA: no
Description: DieTBra + EVOO (52 mL/day)
Study: 32455620
Drug: EVOO (52
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVOO (52 mL/day)
Study: 36382849
Drug: Pevonedistat 25
Normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pevonedistat 25 mg/m2
Study: 36382849
Drug: Pevonedistat 50
Normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pevonedistat 50 mg/m2
Study: 34044563
Drug: Ropivacaine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 10 mL
Study: 34044563
Drug: Ropivacaine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 20 mL
Study: 34044563
Drug: Ropivacaine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 30 mL
Study: 35123662
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors (anastrozole, exemestane, or letrozole)
Study: 35770520
Drug: Mazindol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mazindol (1 mg, twice a day for 6 months)
Study: 35770520
Drug: Mazindol-metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mazindol-metformin (500 mg metformin combined with 1 mg mazindol, twice a day for 6 months)
Study: 33074074
Drug: 1 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 × 10^6 conidia/ml suspension of Colletotrichum siamense
Study: 36208293
Drug: Belimumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belimumab (10 mg/kg intravenous)
Study: 33065817
Drug: Coping with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coping with Depression course with additional daily placebo treatment
Study: 35597959
Drug: Self-guided digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-guided digital treatment comprising psychoeducation and virtual reality exposure therapy (VRET) for 6 weeks, including one therapy session preparing for VRET and 4 weeks of self-guided VRET.
Study: 32858361
Drug: Positive airway
Normalized name: VersaPAP Positive Airway Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive airway pressure (PAP) therapy for at least three months (mean 377.6 ± 419.5 days)
Study: 33483123
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU) - nine sessions
Study: 36388237
Drug: Levodopa-Carbidopa Intestinal
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa-Carbidopa Intestinal Gel (LCIG)
Study: 34236101
Drug: Oral Optimized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Optimized Medical Treatment (OMT)
Study: 33405297
Drug: 140% Insulin-to-Carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140% Insulin-to-Carbohydrate Ratio (ICR)
Study: 33405297
Drug: 160% Insulin-to-Carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160% Insulin-to-Carbohydrate Ratio (ICR)
Study: 33405297
Drug: 100% Insulin-to-Carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% Insulin-to-Carbohydrate Ratio (ICR)
Study: 33405297
Drug: 120% Insulin-to-Carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120% Insulin-to-Carbohydrate Ratio (ICR)
Study: 33405297
Drug: Increasing insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increasing insulin doses (100%-160% ICR)
Study: 32609651
Drug: Expectations toward
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectations toward treatment effects
Study: 32609651
Drug: Unintentional unblinding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unintentional unblinding and patients' perception of treatment
Study: 34267583
Drug: TG4 (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG4 (four weekly campus board training sessions)
Study: 34267583
Drug: TG2 (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG2 (two weekly campus board training sessions)
Study: 36320825
Drug: Withholding methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Withholding methotrexate for 2 weeks after each dose of ChAdOx1 nCov‐19 vaccine (MIVAC I)
Study: 36320825
Drug: Withholding methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Withholding methotrexate for 2 weeks after the second dose of ChAdOx1 nCov‐19 vaccine (MIVAC II)
Study: 35067125
Drug: Robotic assisted
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic assisted training (assisted motion, biofeedback, antagonist muscle vibration)
Study: 36354243
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of magnesium daily (two 250-mg magnesium oxide tablets for five days)
Study: 34881835
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide (Rybelsus®)
Study: 35345663
Drug: Temozolomide single
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide single agent and doxorubicin
Study: 35345663
Drug: Temozolomide capsules
Normalized name: Temozolomide Capsules
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide capsules (control group)
Study: 34495437
Drug: Prophylactic anticonvulsant
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic anticonvulsant use in both aSAH and sICH